Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc, a clinical-stage UK-based biopharmaceutical company focused on rare diseases, covers the month of April 2019. The report serves as a notification of director dealings in accordance with the EU Market Abuse Regulation.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document is strictly a regulatory disclosure of insider trading activity.
Material Changes and Transactions
On April 29, 2019, two senior executives purchased American Depositary Shares (ADSs) on the NASDAQ (XNMS):
- Denise Scots-Knight (CEO): Purchased 6,000 ADSs at an aggregated price of USD 5.887 per ADS.
- Richard Jones (CFO): Purchased 2,025 ADSs at a price of USD 6.04 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a mandatory disclosure of transactions by persons discharging managerial responsibilities.
Investor Verification Points
- Verify the total number of ADSs purchased by the CEO and CFO (8,025 total).
- Confirm the transaction date of April 29, 2019, and the execution venue (XNMS).
- Note that this filing does not reflect the company's operational or financial performance for the period.